Use of preparing drugs for treating non-obstructive hypertrophic cardiomyopathy

Abstract

The present disclosure relates to a use for the manufacture of a medicament for treating non-obstructive hypertrophic cardiomyopathy, and in particular to, use of a compound of Formula I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for preventing and / or treating non-obstructive hypertrophic cardiomyopathy. Compared to Mavacamten and Aficamten, the compound of Formula I or the pharmaceutically acceptable salt thereof of the present disclosure has a shorter time to reach a steady state, higher safety, and no complex drug combination limitation.

Images